| Bioactivity | BTK-IN-22 is a BTK inhibitor (IC50: 0.9 nM). BTK-IN-22 also inhibits BLX and BMX with IC50s of 1.4 and 1.2 nM respectively. BTK-IN-22 shows improved kinase selectivity compared to Ibrutinib (HY-10997)[1] |
| Invitro | BTK-IN-23 (Compound 2) 抑制 Jeko-1 细胞中 BTK 自磷酸化，IC50 值为 109 nM[1]. Western Blot Analysis[1] Cell Line: |
| Name | BTK-IN-22 |
| CAS | 2573048-10-7 |
| Formula | C26H26N6O2 |
| Molar Mass | 454.52 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sean T. Toenjes, et al. Controlling Ibrutinib’s Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity. ACS Med. Chem. Lett. 2023. https://doi.org/10.1021/acsmedchemlett.2c00523 |
BTK-IN-22
CAS: 2573048-10-7 F: C26H26N6O2 W: 454.52
BTK-IN-22 is a BTK inhibitor (IC50: 0.9 nM). BTK-IN-22 also inhibits BLX and BMX with IC50s of 1.4 and 1.2 nM respective
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.